The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database

Area of Science:

• Pharmacology
• Toxicology
• Psychiatry

Background:

• 3,4-methylenedioxymethamphetamine (MDMA) is being explored for treating post-traumatic stress disorder (PTSD).
• Antidepressants are the primary treatment for PTSD, necessitating an understanding of potential drug interactions with MDMA.
• This study investigates the relationship between antidepressant use and MDMA-related fatalities.

Purpose of the Study:

• To examine the association between antidepressant use and fatalities involving 3,4-methylenedioxymethamphetamine (MDMA).
• To analyze data from a national drug-death database to understand drug-drug interactions.
• To assess if antidepressant use influences the risk of MDMA-related death.

Main Methods:

• A retrospective case-control study utilized data from the National Programme on Substance Use Mortality (1997-2023).
• Cases were deaths with MDMA detected, matched by age and sex to controls without MDMA detection.
• Conditional logistic regression adjusted for confounders including polysubstance use and intentionality of death.

Main Results:

• Post-mortem analysis revealed antidepressant use was less likely in MDMA fatalities (aOR 0.595).
• Analysis of prescribed antidepressants showed no significant association with MDMA fatalities (aOR 0.838).
• A total of 1328 cases and 5312 controls were included in the post-mortem analysis.

Conclusions:

• This study found an inverse association between antidepressant use and MDMA fatality.
• Antidepressant use may be less prevalent in individuals who fatally overdose on MDMA.
• Further investigation is warranted to clarify the implications for MDMA-assisted therapies.